S. Ratto-Kim

发表

Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection

Jintanat Ananworanich, Edgar Busovaca, Victor DeGruttola, 2012, PloS one.

Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection

Jerome H. Kim, Zhi Wei, N. Michael, 2012, Retrovirology.

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response.

R. Redfield, D. Birx, N. Aronson, 1999, The Journal of infectious diseases.

Varicella immunity: persistent serologic non-response to immunization.

S. Ratto-Kim, R. Moriarity, R. Katial, 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Jerome H. Kim, P. Earl, B. Moss, 2012, Vaccine.

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens

Jerome H. Kim, P. Earl, B. Moss, 2012, PloS one.

Efﬁcacy Testing of Recombinant Human Immunodeﬁciency Virus (HIV) gp160 as a Therapeutic Vaccine in Early-Stage HIV-1–Infected Volunteers

R. Redfield, C. Tacket, D. Birx, 2022 .

HIV DNA and Dementia in Treatment-Naïve HIV-1-Infected Individuals in Bangkok, Thailand

R. Paul, V. Valcour, K. Robertson, 2006, International journal of medical sciences.

Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

Hongjun Bai, D. Douek, J. Ananworanich, 2022, EBioMedicine.

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1

Jerome H. Kim, L. Jagodzinski, N. Michael, 2015, Scientific Reports.

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.

R. Steinman, J. Mascola, M. Robb, 2002, The Journal of infectious diseases.

Material for Adjuvant dependent innate and adaptive immune signatures of risk of SIVmac 251 acquisition

Karen G. Dowell, Christopher J. Miller, C. Bailey-Kellogg, 2016 .

Activated PD-1+ CD4 T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART.

J. Baeten, M. McElrath, E. Sanders-Buell, 2019, AIDS.

A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost

Jerome H. Kim, D. Birx, R. Paris, 2007, Journal of acquired immune deficiency syndromes.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Karen G. Dowell, Jerome H. Kim, C. Bailey-Kellogg, 2016, Nature Medicine.

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection

Jerome H. Kim, R. Redfield, M. Ferguson, 2016, PLoS pathogens.

HIV-1 Envelope Resistance to Proteasomal Cleavage: Implications for Vaccine Induced Immune Responses

Jerome H. Kim, M. de Souza, N. Michael, 2012, PloS one.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Jerome H. Kim, L. Jagodzinski, M. Robb, 2016, The Journal of infectious diseases.

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene

J. Excler, J. Cox, S. Ratto-Kim, 2012, Retrovirology.

Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons.

M. Connors, D. Birx, B. Levine, 2004, Clinical immunology.

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection

D. Birx, B. Levine, C. June, 2002, Nature Medicine.

Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.

J. Mascola, M. Robb, N. Michael, 2001, AIDS research and human retroviruses.

Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.

S. Zolla-Pazner, M. Gorny, C. Münz, 2000, AIDS research and human retroviruses.

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.

M. Robb, D. Birx, A. Hodgkins, 1999, The Journal of infectious diseases.

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

R. Redfield, D. Birx, S. Ratto-Kim, 1997, The Journal of infectious diseases.

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges

Jerome H. Kim, R. Paris, J. Excler, 2018, Front. Immunol..

Circulating proviral HIV DNA and HIV-associated dementia

V. Valcour, M. Watters, B. Shiramizu, 2005, AIDS.

Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.

Jerome H. Kim, R. Redfield, L. Jagodzinski, 2004, The Journal of infectious diseases.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost

P. Earl, B. Moss, N. Sardesai, 2017, The Journal of infectious diseases.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Allan C. deCamp, Jerome H. Kim, D. Montefiori, 2017, The Journal of infectious diseases.

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.

R. Moss, D. Venzon, M. Robb, 1999, The Journal of infectious diseases.

Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function

D. Birx, N. Michael, D. Mayers, 1997, Journal of virology.

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.

Jerome H. Kim, P. Pitisuttithum, S. Nitayaphan, 2012, Vaccine.

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

Jaranit Kaewkungwal, Nelson L Michael, Supachai Rerks-Ngarm, 2012, The Journal of Immunology.

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

Jerome H. Kim, D. Birx, R. El Habib, 2003, Journal of acquired immune deficiency syndromes.

Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders.

Jerome H. Kim, R. Paul, D. Clifford, 2018, AIDS research and human retroviruses.

Association between brain volumes and HAND in cART-naïve HIV+ individuals from Thailand

R. Paul, D. Clifford, J. Ananworanich, 2015, Journal of NeuroVirology.

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants

Jerome H. Kim, J. Mullins, E. Sanders-Buell, 2014, PloS one.

Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV-1 infection

R. Paul, J. McArthur, V. Valcour, 2007, Neurology.

Cellular immune assays for evaluation of vaccine efficacy in developing countries

D. Birx, G. Ferrari, K. Weinhold, 2002 .

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania

F. Mccutchan, M. Hoelscher, L. Maboko, 2009, Retrovirology.

Designing the epitope flanking regions for optimal generation of CTL epitopes.

Jerome H. Kim, N. Michael, C. Alving, 2014, Vaccine.

Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4 Binding Domain of gp120

S. Zolla-Pazner, M. Gorny, D. Nixon, 2001, Journal of Virology.

Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection

M. Robb, D. Guwatudde, M. de Souza, 2012, Journal of acquired immune deficiency syndromes.

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

Jerome H. Kim, P. Earl, B. Moss, 2010, PloS one.

Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand

Jerome H. Kim, V. Valcour, K. Williams, 2008, Journal of Neuroimmunology.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals

Jerome H. Kim, Zhi Wei, R. Koup, 2014, Proceedings of the National Academy of Sciences.

HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages?

Jerome H. Kim, V. Valcour, M. Gerschenson, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals.

J. Silver, D. Birx, D. Mann, 1997, Journal of immunology.

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

R. Redfield, C. Tacket, D. Birx, 2000, The Journal of infectious diseases.

Peptide Impurities in Commercial Synthetic Peptides and Their Implications for Vaccine Trial Assessment

H. Wenschuh, C. Gray, M. Hoelscher, 2007, Clinical and Vaccine Immunology.

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response

Jerome H. Kim, S. Ratto-Kim, Haitao Hu, 2016, Expert review of vaccines.

Region of HIV-1 Envelope Preferentially Target Epitopes within the V2 Regimen Induces T Cell Responses That The Thai Phase III Trial (RV144) Vaccine

S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, 2012 .

HIV DNA and cognition in a Thai longitudinal HAART initiation cohort

R. Paul, J. Ananworanich, V. Valcour, 2009, Neurology.